Form 4: Royalty Pharma Director Errol B. DeSouza Receives Stock Award

Director Errol B. DeSouza receives 7,614 Class A Ordinary Shares of Royalty Pharma plc as a restricted stock unit award.

Summary

• Errol B. DeSouza, a director of Royalty Pharma plc, received 7,614 Class A Ordinary Shares on May 13, 2025.
• The shares were awarded as restricted stock units under the company's 2020 Independent Director Equity Incentive Plan.
• The restricted stock units are scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date.
• Following the transaction, DeSouza directly owns 81,352 Class A Ordinary Shares.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of awarding stock to directors, which is generally viewed positively as it aligns interests. There are no indications of negative news or concerns.

Positives

• The grant of restricted stock units aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The vesting of the restricted stock units is contingent upon the terms of the 2020 Independent Director Equity Incentive Plan and the applicable award agreement.

Industry Context

Stock awards to directors are a common practice to incentivize and align their interests with the company's long-term performance and shareholder value.

Stakeholder Impact

• The stock award aligns the director's interests with those of the shareholders, potentially leading to better corporate governance and decision-making.
• The award does not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Royalty Pharma, Director, Errol B. DeSouza, Stock Award, Restricted Stock Units, RPRX, Equity Incentive Plan, Beneficial Ownership